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Stellingen	
behorende	bij	het	proefschrift	
	
Gene	therapy	and	nerve	repair.	
	
1. Despite	major	microsurgical	improvements	the	clinical	outcome	of	peripheral	nerve	
surgery	is	suboptimal.	
	
2. To	enhance	peripheral	nerve	regeneration	new	treatments	should	aim	at	1)	
increasing	the	number	of	axons	successfully	crossing	surgical	coaptation	sites;	2)	
increasing	the	velocity	of	regenerating	axons	3)	preventing	misrouting	of	axons;	4)	
keeping	Schwann	cells	in	a	pro-regenerative	state,	and	5)	preventing	atrophy	of	
denervated	end-organs.		
	
3. Viral	vector	mediated	overexpression	of	neurotrophic	factors	may	be	applied	as	a	
strategy	to	increase	the	number	of	regenerating	axons	and	to	overcome	their	
misrouting.	(this	thesis;	and	Hu	et	al.	Exp.	Neurol.	2010;	223:153–165)		
	
4. Chronic	exposure	to	neurotrophic	factors	results	in	local	trapping	of	regenerating	
axons.	Therefore,	tight	control	of	therapeutic	gene	expression	is	required.	(this	
thesis)		
	
5. Our	potentially	immune-evasive	inducible	viral	vector	represents	the	first	prototype	
of	a	clinically	applicable	inducible	gene	therapy	vector.	(this	thesis)	
	
6. The	adeno-associated	viral	vector	(AAV)	is	gaining	increasing	acceptance	as	a	
clinically	safe	gene	therapy	vector	and	can	be	used	successfully	to	target	the	
Schwann	cells	in	the	human	peripheral	nervous	system.	(this	thesis)	
	
7. “Recent	clinical	trials	of	gene	therapy	have	shown	remarkable	therapeutic	benefits	
and	an	excellent	safety	record.	They	provide	evidence	for	the	long-sought	promise	of	
gene	therapy	to	deliver	'cures'	for	some	otherwise	terminal	or	severely	disabling	
conditions”.	(Naldini	et	al.	Nature.	2015;	526:351-360)		
	
8. The	approval	and	marketing	authorization	in	2012	of	Glybera©	(Uniqure),	a	first	
AAV-based	gene	therapy	product	to	treat	lipoprotein	lipase	deficiency	(LPLD),	has	
been	a	major	milestone	for	the	field	of	gene	therapy.		
	
9. Research	takes	time,	time	costs	money,	money	costs	headaches	
	
10. If	the	human	brain	were	so	simple	that	we	could	understand	it,	we	would	be	so	
simple	that	we	couldn’t.	(George	Edgin	Pugh,	The	Biological	Origin	of	Human	Values	
(1977))	
	
11. "They’ve	done	studies…	60%	of	the	time,	it	works	every	time"	(Brian	Fantana.	
Anchorman	The	Legend	of	Ron	Burgundy	(2004))	
	
12. "On	ne	voit	bien	qu’avec	le	coeur.	L’essentiel	est	invisible	pour	les	yeux”	(Antoine	de	
Saint-Exupéry,	Le	Petit	Prince	(1943))	
	
